156 related articles for article (PubMed ID: 14744180)
1. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome.
Ballard CG; Thomas A; Fossey J; Lee L; Jacoby R; Lana MM; Bannister C; McShane R; Swann A; Juszczak E; O'Brien JT
J Clin Psychiatry; 2004 Jan; 65(1):114-9. PubMed ID: 14744180
[TBL] [Abstract][Full Text] [Related]
2. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
3. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa.
Ballard CG; O'Brien JT; Reichelt K; Perry EK
J Clin Psychiatry; 2002 Jul; 63(7):553-8. PubMed ID: 12143909
[TBL] [Abstract][Full Text] [Related]
4. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).
Ballard C; Lana MM; Theodoulou M; Douglas S; McShane R; Jacoby R; Kossakowski K; Yu LM; Juszczak E;
PLoS Med; 2008 Apr; 5(4):e76. PubMed ID: 18384230
[TBL] [Abstract][Full Text] [Related]
5. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.
Katz IR; Jeste DV; Mintzer JE; Clyde C; Napolitano J; Brecher M
J Clin Psychiatry; 1999 Feb; 60(2):107-15. PubMed ID: 10084637
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial.
Bergh S; Selbæk G; Engedal K
BMJ; 2012 Mar; 344():e1566. PubMed ID: 22408266
[TBL] [Abstract][Full Text] [Related]
8. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities.
Fontaine CS; Hynan LS; Koch K; Martin-Cook K; Svetlik D; Weiner MF
J Clin Psychiatry; 2003 Jun; 64(6):726-30. PubMed ID: 12823090
[TBL] [Abstract][Full Text] [Related]
9. Do Hearing Aids Influence Behavioral and Psychological Symptoms of Dementia and Quality of Life in Hearing Impaired Alzheimer's Disease Patients and Their Caregivers?
Adrait A; Perrot X; Nguyen MF; Gueugnon M; Petitot C; Collet L; Roux A; Bonnefoy M;
J Alzheimers Dis; 2017; 58(1):109-121. PubMed ID: 28269769
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial.
Ihl R; Bachinskaya N; Korczyn AD; Vakhapova V; Tribanek M; Hoerr R; Napryeyenko O;
Int J Geriatr Psychiatry; 2011 Nov; 26(11):1186-94. PubMed ID: 21140383
[TBL] [Abstract][Full Text] [Related]
11. Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment-controlled pilot study.
Bridges-Parlet S; Knopman D; Steffes S
J Geriatr Psychiatry Neurol; 1997 Jul; 10(3):119-26. PubMed ID: 9322135
[TBL] [Abstract][Full Text] [Related]
12. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
[TBL] [Abstract][Full Text] [Related]
13. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders.
Cummings JL; McRae T; Zhang R;
Am J Geriatr Psychiatry; 2006 Jul; 14(7):605-12. PubMed ID: 16816014
[TBL] [Abstract][Full Text] [Related]
14. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
[TBL] [Abstract][Full Text] [Related]
16. Does paracetamol improve quality of life, discomfort, pain and neuropsychiatric symptoms in persons with advanced dementia living in long-term care facilities? A randomised double-blind placebo-controlled crossover (Q-PID) trial.
van Dam PH; Achterberg WP; Husebo BS; Caljouw MAA
BMC Med; 2020 Dec; 18(1):407. PubMed ID: 33342434
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.
Cummings JL; Nadel A; Masterman D; Cyrus PA
J Geriatr Psychiatry Neurol; 2001; 14(2):101-8. PubMed ID: 11419566
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.
Paleacu D; Barak Y; Mirecky I; Mazeh D
Int J Geriatr Psychiatry; 2008 Apr; 23(4):393-400. PubMed ID: 17879256
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials.
Ma H; Huang Y; Cong Z; Wang Y; Jiang W; Gao S; Zhu G
J Alzheimers Dis; 2014; 42(3):915-37. PubMed ID: 25024323
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
